Ribociclib-induced phototoxicity - the era of new drugs and new toxicities by Bobić Simonida, Poparić-Banđur Bojana, Matović Milana, Pavlović Lidija, Milović-Kovačević Marijana

Subjects: “…ribociclib…”
Get full text

A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia by John Fernando Montenegro, Giovanna Patricia Rivas-Tafurt, Sinthia Vidal-Cañas, Miguel Ángel Diaz-Diaz, Cesar Eduardo Bermudez, Daniel Florez, Andres Felipe Bravo-Gustin, Yamil Liscano

Subjects: Get full text

Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross... by Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu

Subjects: Get full text

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY by E. V. Artamonova

Subjects: Get full text

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negat... by Manoela Manova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Margit Hemetsberger, Arkadi Sharkov, Boryana Zidarova, Dimitrina Apostolova, Maria Vasileva, Silvia Terezova, Mila Vlaskovska, Alexandra Savova

Subjects: “…Ribociclib…”
Get full text

Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume by Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin

Subjects: Get full text

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities by Mashael Algethami, Ahmed Shoqafi, Ayat Lashen, Shatha Alqahtani, Jake Spicer, Ahmad ALtayyar, Çağla Tosun, Jennie N Jeyapalan, Nigel P. Mongan, Victoria James, Emad A. Rakha, Srinivasan Madhusudan

Subjects: Get full text

Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality by N. A. Avxentyev, E. V. Bilan, A. Yu. Goryainova, Yu. V. Makarova, R. A. Murashko, A. V. Sobolev, S. V. Sharov, D. Yu. Yukalchuk

Subjects: Get full text

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors by Zehra Sucuoğlu İşleyen, Harun Muğlu, Zeynep Alaca Topçu, Mehmet Beşiroğlu, Ayşe İrem Yasin, Atakan Topçu, Melih Şimşek, Mesut Şeker, Hacı Mehmet Türk

Subjects: Get full text

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer by Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang

Subjects: Get full text

Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature by Bhavika Kothari, Pallavi Parab, Seema Gulia, Sushmita Rath, Sudeep Gupta

Subjects: Get full text

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast by Abhira Deb, Manthan Dhingra, Srutee Barman, Thinakaran Raja, Abhra Ghosh

Subjects: Get full text

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III by Nicola Battelli, Carmela Mocerino, Michele Montedoro, Mirco Pistelli, Ilaria Portarena, Mario Rosanova, Tina Sidoni, Patrizia Vici

Subjects: Get full text

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments by Zihan Liu, Zihan Liu, Wenyu Du, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li

Subjects: Get full text

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer by Tamojit Chaudhuri, K Govind Babu, K C Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, M C Suresh Babu, A H Rudresha, K N Lokesh, L K Rajeev

Subjects: Get full text

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy by İrem Öner, Hicran Anık, Bediz Kurt İnci, Pınar Kubilay Tolunay, Öztürk Ateş, Ülkü Yalçıntaş Arslan, Cengiz Karaçin

Subjects: Get full text

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER by N. A. Avksentyev, M. V. Zhuravleva, E. M. Pazukhina, A. V. Snegovoy, M. Yu. Frolov

Subjects: Get full text

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov

Subjects: Get full text

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literat... by N. A. Avxentyev, I. I. Andreyashkina, E. V. Artamonova, L. V. Bolotina, E. I. Kovalenko, N. N. Sisigina

Subjects: Get full text

Structural stability, electronic, and thermodynamic insights into Ribociclib encapsulation in PEG-functionalized ZnO nanocarriers by Mahboubeh Pishnamazi, Kamal Y. Thajudeen, Mohammed Muqtader Ahmed, Saad Ali Alshehri

Subjects: “…Ribociclib…”
Get full text